Inhibiting human monoamine oxidase (MAO)-B to increase the availability of monoamine neurotransmitters is a clinically approved strategy for treating Parkinson’s disease, yet available inhibitors lack efficacy or increase risk of adverse events. Researchers at Hefei University of Technology and collaborators started from the clinically improved MAO-B inhibitor safinamide and generated various derivatives, among which [I] and [II] emerged as the most promising.

Researchers from Cincinnati Children’s Hospital Medical Center and collaborating institutions in the U.S. have developed a novel approach using allergen-encoding mRNA encapsulated in lipid nanoparticles (LNPs) for both therapy and prevention of allergic responses.

Familial dysautonomia (FD) is an autosomal recessive neurodevelopmental disorder.

Cyclana Bio Ltd. has closed a £5 million (US$6.7 million) pre-seed funding round.

A year and half from its inception, Adcytherix SAS has raised a €105 million (US$122 million) series A, enabling it to take the lead antibody-drug conjugate (ADC) program into clinical development next year.